Abstract: An information processing apparatus according to an embodiment includes a hardware processor connected to a memory. The hardware processor estimates a first disease incidence probability of a disease based on first information about expression levels of one or more types of biomarkers of a specimen. The hardware processor estimates a second disease incidence probability of a disease type based on the first information and the first disease incidence probability.

Abstract: A sample identification method according to an embodiment includes setting a first reference sequence that includes a first sequence having a single base substitution site, the single base substitution site being a first base, and a corresponding second reference sequence, outputting the number of first short-chain nucleic acids having the first reference sequence and the number of second short-chain nucleic acids having the second reference sequence, calculating a ratio, obtaining a magnitude relationship between the ratio and a threshold value, and determining, from the number of sequences in which the ratio is greater than the threshold value, whether a subject from whom the sample is derived has the disease or at risk of developing the disease.

Abstract: According to one embodiment, an analysis method for determining a presence or absence of pancreatic cancer in a test subject, comprising quantifying corrective miRNA and target miRNAs in a sample derived from the test subject, wherein the target miRNAs are three or more selected from a group consisting of hsa-miR-205-5p, hsa-miR-223-5p, hsa-miR-29c-3p, hsa-miR-324-3p, hsa-miR-34a-5p, hsa-miR-483-5p and hsa-miR-885-5p.

Abstract: According to one embodiment, method of identifying feature of test body is provided. The method includes measuring a mutation-specific concentration of at least one miRNA contained in the test body, correcting a value of the mutation-specific concentration, and determining whether the test body is a cancer or a non-cancer one using an increase or decrease in the corrected mutation-specific concentration as index.

Abstract: An analysis method may determine the presence of affection of at least any one of breast cancer, pancreatic cancer, lung cancer, gastric cancer, and colorectal cancer. The analysis method may include quantifying at least any one of hsa-miR-205-5p, hsa-miR-30e-5p, hsa-miR-106b-5p, hsa-miR-3613-5p, hsa-miR-483-5p, hsa-miR-574-3p, hsa-miR-125b-5p, hsa-miR-223-5p, hsa-miR-3613-3p, hsa-miR-941, hsa-miR-324-3p, hsa-miR-193a-5p, hsa-miR-4433a-3p, hsa-miR-29c-3p, hsa-miR-190a-5p, hsa-miR-885-5p, hsa-miR-194-5p, hsa-miR-29a-3p, hsa-miR-142-5p, hsa-miR-142-3p, hsa-miR-122-5p, hsa-miR-34a-5p, and hsa-miR-375-3p in a sample derived from an object.

Abstract: According to one embodiment, a method for analyzing the probability of suffering from cancer in a subject is provided. The method includes counting the number of types of RNA in a sample derived from the subject with respect to the types of RNAs in which sequence variation based on RNA editing exists in comparison with a reference sequence, and determining the probability of suffering from cancer in the subject by using the number of types of RNAs obtained as an index.

Abstract: In the present invention, a fraction (A) is labeled, the fraction (A) being a fraction obtained from a maternal blood sample and in which nucleated red blood cells (NRBCs) are concentrated in a population of whole blood cells. Then, a fraction (B) having increase purity of NRBCs is obtained by sorting out blood cells in the labeled fraction A by at least cell sorting. Next, fractions (C) are obtained by separating each blood cell in the fraction (B) at a single-cell level and independently performing a process for extracting a nucleic acid for each separated blood cell, each of the fractions (C) containing a nucleic acid distinguishable at a single-cell level. Then, a fraction (D) containing a nucleic acid derived from a fetus is sorted out from a group of fractions (C) by performing a molecular biological analysis for each of the fractions (C).

Abstract: In the present invention, a fraction (A) is labeled, the fraction (A) being a fraction obtained from a maternal blood sample and in which nucleated red blood cells (NRBCs) are concentrated in a population of whole blood cells. Then, a fraction (B) having increase purity of NRBCs is obtained by sorting out blood cells in the labeled fraction A by at least cell sorting. Next, fractions (C) are obtained by separating each blood cell in the fraction (B) at a single-cell level and independently performing a process for extracting a nucleic acid for each separated blood cell, each of the fractions (C) containing a nucleic acid distinguishable at a single-cell level. Then, a fraction (D) containing a nucleic acid derived from a fetus is sorted out from a group of fractions (C) by performing a molecular biological analysis for each of the fractions (C).